Recruiting a CFO with Pharma-Specific IP and Patent Knowledge

At JRG Partners, this is the kind of search we run every day, so this piece reflects practice rather than theory. A pharmaceutical CFO operates in a business where intellectual property is often the principal asset, patent expiry defines the revenue horizon, and litigation outcomes can move valuation more than operating performance. A CFO who treats IP as the legal department’s concern will misjudge forecasting, capital allocation, and how investors actually value the company.

IP Determines the Revenue Horizon

In pharmaceutical companies, the duration of exclusivity on key products effectively sets the shape of future revenue, and everything downstream, capital allocation, business development priorities, investor communication, follows from it. A CFO must understand the patent estate well enough to model loss of exclusivity credibly, including the mechanics that affect timing: patent term adjustments and extensions, regulatory exclusivities that run alongside patents, pediatric extensions where applicable, and the practical erosion curves that follow generic or biosimilar entry. This is finance work, not legal work, even though it depends on legal input.

Modelling Erosion Realistically

Loss-of-exclusivity forecasting is where pharmaceutical CFOs most often err, because erosion varies substantially by product type, market, and competitive dynamics. Small molecule erosion after generic entry typically differs from biologic erosion after biosimilar entry, and both differ across markets depending on substitution rules and payer behaviour. A CFO who applies a generic erosion assumption across a portfolio produces forecasts that mislead the board and investors. Assess whether candidates have built these models themselves and can explain the assumptions they used and where they proved wrong.

Litigation as a Financial Variable

Patent challenges, infringement suits, and settlements are routine in pharmaceuticals and can materially alter revenue timing. A CFO need not be a litigator, but must be able to work closely with legal to understand case posture, model scenarios rather than single outcomes, judge what should be disclosed and how, and avoid the twin errors of ignoring litigation risk and presenting settlements as certainties. Candidates who have managed financial planning through significant patent litigation bring judgment that is difficult to acquire otherwise.

IP in Business Development Decisions

Pharmaceutical business development, in-licensing, out-licensing, acquisitions, partnering, turns heavily on IP position, and the CFO is central to valuing these transactions. Assessing what an asset is worth requires understanding the strength and duration of its protection, the freedom-to-operate position, and how royalty and milestone structures interact with the exclusivity horizon. A CFO who cannot engage substantively with these questions will rely entirely on others’ judgment in transactions that frequently determine the company’s future, which is a significant gap at this level.

What This Looks Like in Practice

A pharmaceutical company hiring a CFO assesses whether the candidate has personally built loss-of-exclusivity models and can explain their assumptions, has managed financial planning through patent litigation, and can engage substantively with IP considerations in licensing and acquisition valuation rather than deferring entirely to legal colleagues.

The Mistake Employers Keep Making

The most common mistake is hiring a strong general CFO, or one from another regulated industry, and assuming the IP dimension can be handled by legal counsel. The CFO then builds forecasts on erosion assumptions they cannot defend, presents litigation exposure poorly to investors, and cannot independently assess business development valuations. Financial capability is mistaken for pharmaceutical financial capability.

IP Dimensions a Pharma CFO Must Command

The Bottom Line

A pharmaceutical CFO must command the IP dimension directly, modelling loss of exclusivity credibly by product type and market, planning through litigation scenarios, and valuing business development against protection horizons, so assess this specifically rather than assuming strong general financial leadership covers it. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.

Related Reading

For more, see Recruiting Leadership for Generic Drug Manufacturers, Hiring Executives with Both Innovator and Generics Experience, What Sets Top Pharma Executive Recruiters Apart.

Tanya Gallardo

Managing Director, Executive Search & AI Talent Strategy

Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.

With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.

Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.

Connect with Tanya to discuss your executive search needs.